Abbott, Cordis-backed study challenges stent options for coronary bifurcation lesions

An international clinical trial funded, in part, by Abbott ($ABT) and Johnson & Johnson's ($JNJ) Cordis concluded that using a two-stent technique to treat coronary bifurcation lesions with a large stenotic side branch didn't work any better than a provisional stenting approach. The Nordic-Baltic Bifurcation IV study looked at 450 patients with coronary bifurcation lesions, randomized 1:1. Surgeons used a provisional strategy on one group (stenting of the main vessel and provisional stenting of the side branch) and a complex two-stent strategy on the other (planned stenting for both the main vessel and side branch). Rates of major adverse cardiac events were about the same for both groups, the researchers said. But longer and more complex procedures for the two-stent group didn't lead to more procedure-related heart attacks. Researchers presented their findings at the 25th annual Transcatheter Cardiovascular Therapeutics scientific symposium in San Francisco. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.